Humacyte, Inc. HUMA

Humacyte, Inc. closes at $0.56, down 2% as the S&P 500 and Nasdaq rise; the stock has fallen 17.9% over the past month, underperforming the Medical sector and the broader market. Ahead of the next earnings release, Humacyte is expected to report earnings of -$0.09 per share, representing year-over-year growth of 35.71%, on about $0.86 million in revenue, up 14.67% from a year earlier. Full-year consensus calls for -$0.40 per share and $4.05 million in revenue, a 53.85% decline in earnings and a 98.48% rise in revenue. Zacks Rank remains #3 (Hold), with the Medical - Biomedical and Genetics industry ranking in the bottom half. The report notes that recent analyst estimate revisions can influence near-term stock movement. Earnings expectations and flat consensus suggest a modest near-term impact rather than a transformative shift.

FDA authorizes Humacyte to extend Symvess shelf life to 36 months. Extending Symvess shelf life to 36 months improves product logistics and supports wider clinical adoption.

Humacyte confirms plans to file supplemental BLA for ATEV in dialysis access after FDA discussions. FDA-aligned ATEV filing plans for dialysis access mark major regulatory step toward potential approval and revenue in core indication.

Humacyte (HUMA) released its Q2 2026 earnings call transcript covering financial results, operational updates, and strategic outlook. Earnings call transcript delivers financial results and guidance with direct effect on valuation and investor positioning.

Humacyte announces Lancet Digital Health publication of V007 Phase 3 trial results for hemodialysis access. Phase 3 trial publication in major journal boosts trial credibility and supports future regulatory and commercial prospects.

A board-certified vascular and endovascular surgeon performed the first commercial implantation of Humacyte's Symvess bioengineered blood vessel and described it as a revolutionary advancement. First commercial use of flagship product advances revenue generation and market adoption.

Humacyte reports stronger Phase 3 dialysis results in women. Stronger Phase 3 dialysis results in women boost prospects for regulatory approval and commercial success.

Humacyte Inc (HUMA) presented strong trial results and strategic updates in its Q2 2026 earnings call. Strong trial results signal major clinical progress that can drive regulatory and commercial momentum.

Humacyte, Inc. held its Q2 2026 earnings call, outlining quarterly financial results, operational progress, and forward-looking statements on product development and market strategy. Earnings call details financial performance and strategic updates that can materially shift investor views and company direction.

Humacyte held its Q2 earnings call and released highlights covering financial results, operational updates, and pipeline progress. Quarterly earnings updates typically offer moderate insight into near-term financials and strategy without altering long-term trajectory.

Humacyte reported second quarter 2026 financial results and provided a business update. Quarterly results and updates can moderately shift investor views on financial position and pipeline progress.

Humacyte announces FDA acceptance of IND for first-in-human clinical study of CTEV for coronary artery bypass grafting. FDA acceptance launches first-in-human trials of CTEV advancing Humacyte's core vascular graft pipeline.

Humacyte appoints key nephrologists as advisors to prepare for planned commercialization of its ATEV in dialysis access. Advisor appointments advance Humacyte's ATEV commercialization prep and may modestly influence market positioning and sentiment ahead of launch.

Humacyte (HUMA) stock fair value falls amid split analyst views following V012 data. Split analyst views after V012 data cut HUMA stock fair value and may sway near-term sentiment.

Humacyte's bioengineered blood vessel outperformed standard care for women on dialysis in Phase 3 results presented at the Society for Vascular Surgery Vascular Annual Meeting. Phase 3 success for lead bioengineered vessel in dialysis patients signals major regulatory and commercial upside.

Humacyte reports ATEV met late-stage study endpoint in interim analysis and launches public offering, causing shares to fall. Positive ATEV trial data marks major clinical progress for Humacyte's lead asset despite dilution risk from offering and immediate share decline.

Humacyte ATEV met superiority primary endpoint versus standard AV fistula in interim analysis of V012 Phase 3 study for female dialysis access patients. Positive Phase 3 data for lead ATEV candidate supports regulatory progress and revenue potential in dialysis access.

Humacyte prices public offering of common stock. Equity offering raises funds while diluting shares and pressuring near-term valuation.

Humacyte, Inc. announces proposed public offering of common stock. Proposed public offering enables capital raise for Humacyte operations while introducing share dilution that can pressure stock price and market sentiment.

Humacyte stock plunged after hours due to a proposed share offering, despite strong dialysis data. Proposed share offering triggers immediate dilution and price drop while dialysis data supports ongoing product progress.

Humacyte held its Q1 2025 earnings call, covering financial results, operational updates, and forward outlook for the company's bioengineered human tissue products. Quarterly earnings provide financial metrics and pipeline updates that can shift near-term investor views but rarely alter long-term trajectory for clinical-stage biotech firms.

Humacyte shares rise 23.8% on long-term data demonstrating self-repair properties for its dialysis technology, prompting questions on whether the prior bull case has shifted. Positive long-term dialysis data drives major stock surge and reevaluation of Humacyte growth prospects.

Humacyte presented research at VASA Meeting demonstrating self-repair capability of ATEV following cannulation for dialysis access. Positive ATEV data presentation can modestly support product positioning in dialysis without immediate regulatory or commercial changes.

Humacyte announces Symvess is now under contract with the Strategic Acquisition Center of the U.S. Department of Veterans Affairs. VA contract opens direct access to veteran healthcare facilities and potential revenue growth for Symvess.

Analysts raised Humacyte, Inc. (HUMA) price target despite early-stage commercialization. Price target increase signals moderately improved market sentiment for Humacyte without altering core commercialization trajectory.

Humacyte Inc. (HUMA) reported surging sales and strategic expansions in Q1 2026 earnings call highlights amid ongoing challenges. Surging sales and strategic expansions represent major positive developments likely to boost financial performance and investor sentiment.

Humacyte (HUMA) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance, strategic initiatives, and guidance that significantly influence HUMA's trajectory and investor sentiment.

Humacyte, Inc. (HUMA) released highlights from its Q1 earnings call, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights detail financial performance, pipeline progress, and strategic outlook with potential to significantly sway investor sentiment and stock trajectory.

Humacyte, Inc. (HUMA) reported Q1 2026 financial results, with the full earnings call transcript released. Q1 earnings results and call details can significantly impact stock performance and investor outlook for biotech firms like Humacyte.

Humacyte, Inc. (HUMA) reported a Q1 net loss and missed revenue estimates. Q1 loss and revenue miss moderately impacts financial performance and investor sentiment.